(Q34481715)

2 August 2017

1 reference

title

Therapeutic potential of angiotensin II receptor antagonists (English)

1 reference

2 August 2017

White M

1

1 reference

2 August 2017

Racine N

series ordinal

2

1 reference

2 August 2017

Ducharme A

series ordinal

3

1 reference

2 August 2017

de Champlain J

series ordinal

4

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 September 2001

1 reference

Expert Opinion on Investigational Drugs

2 August 2017

1 reference

2 August 2017

10

1 reference

2 August 2017

9

1 reference

2 August 2017

1687-1701

1 reference

Preliminary biochemical characterization of two angiotensin II receptor subtypes

2 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Role of angiotensin AT1, and AT2 receptors in cardiac hypertrophy and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Matrix-dependent gene expression of egr-1 and PDGF A regulate angiotensin II-induced proliferation in human vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Brain renin-angiotensin system and ouabain-induced sympathetic hyperactivity and hypertension in Wistar rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Angiotensin receptors and their antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Mechanisms of relaxation induced by angiotensin II in isolated canine and human uterine arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Arterial function in nitric oxide-deficient hypertension: influence of long-term angiotensin II receptor antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Angiotensin II, adhesion, and cardiac fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Angiotensin II signal transduction in vascular smooth muscle: role of tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH-/NADPH-oxidases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Modulation of extracellular superoxide dismutase expression by angiotensin II and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Modulation of sympathetic coronary vasoconstriction by cardiac renin-angiotensin system in human coronary heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Differential role of angiotensin II receptor subtypes on endothelial superoxide formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Angiotensin II binding in area postrema and nucleus tractus solitarius of SHR and WKY rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Effect of blocking angiotensin II receptor subtype on rat sympathetic nerve function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Histology of subcutaneous small arteries from patients with essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Baroreflex sensitivity and cardiovascular mortality in patients with mild to moderate heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Endogenous angiotensin II and baroreceptor dysfunction: a comparative study of losartan and enalapril in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Left ventricular hypertrophy and angiotensin II antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Valsartan in acute myocardial infarction trial (VALIANT): rationale and design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Angiotensin II type 1 receptor blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1687

10.1517/13543784.10.9.1687

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference